You just read:

Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

News provided by

Frontier Biotechnologies Inc.

Jun 06, 2016, 01:49 ET